DOCSLIB.ORG

44644 Report 4C Pgs Interior.Indd

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
44644 Report 4C Pgs Interior.Indd First and foremost, we are committed to delivering quality, affordable healthcare products that improve 2008 ANNUAL REPORT T H E R I G H T P L A C E . Y . T H E R I G H P A N the quality of people’s lives. T T I M E . T H E R I G H T C O M 515 Eastern Avenue Allegan, Michigan 49010 (269) 673-8451 www.perrigo.com 2008 ANNUAL REPORT ©2008 Perrigo Company. All rights reserved. Shareholder Information Directors Executive Offi cers Independent Accountants Joseph C. Papa Through fi scal 2008, Chairman, President and BDO Seidman, LLP Chief Executive Offi cer Grand Rapids, Michigan Judy L. Brown Commencing fi scal 2009, Executive Vice President and Ernst & Young, LLP Chief Financial Offi cer Grand Rapids, Michigan Thomas M. Farrington Senior Vice President and Chief Fiscal 2008 Cash Information Offi cer Dividend Data John T. Hendrickson Fiscal Record Payable Per Share Executive Vice President, Global Quarter Date Date Amount Operations and Supply Chain 1st 8/24/07 9/18/07 $0.045 Moshe Arkin Laurie Brlas Gary M. Cohen Todd W. Kingma Former Vice Chairman, Senior Vice President, Executive Vice President, Executive Vice President, 2nd 11/23/07 12/18/07 $0.050 Perrigo Company Chief Financial Offi cer Becton, Dickinson and Company General Counsel and Secretary Director since 2005 and Treasurer, Director since 2003 3rd 2/22/08 3/18/08 $0.050 Cleveland-Cliffs, Inc. Sharon Kochan Director since 2003 Executive Vice President, U.S. Generics 4th 5/25/08 6/20/08 $0.050 Refael Lebel Executive Vice President and President, Perrigo Israel Shareholder Account Information Jeffrey R. Needham Senior Vice President, Shareholders with requests for Commercial Business Development information regarding their share position, stock certifi cates, address Jatin Shah changes and other related matters Senior Vice President, should contact: Chief Scientifi c Offi cer National City Bank Corporate Trust Operations Michael R. Stewart P.O. Box 92301 Senior Vice President, Cleveland, Ohio 44193-0900 Global Human Resources (800) 622-6757 James C. Tomshack Senior Vice President, Financial Information Consumer Healthcare Sales David T. Gibbons Ran Gottfried Ellen R. Hoffi ng Michael J. Jandernoa Annual reports, news releases, Dr. Louis W. Yu Former Chairman of the Board, Consultant and Director President and Former Chairman of the Board, earnings announcements, dividend Senior Vice President, Perrigo Company for public and private Chief Executive Offi cer, Perrigo Company announcements, Form 10-K, 10-Q Global Quality and Compliance Director since 2000 companies in Israel Applied NeuroSolutions, Inc. Director since 1981 and 8-K reports and other fi nancial Director since 2006 Director since 2008 information may be obtained by visiting Corporate Profi le the investor relations section of our Share Information Web site: www.perrigo.com/investors. Perrigo Company common stock is traded ® Perrigo Company is a leading global healthcare supplier that develops, on The NASDAQ Global Select Market and the Tel Aviv Stock Exchange (TASE) Investor Relations Contact under the symbol PRGO. Shares manufactures and distributes over-the-counter (OTC) and generic prescription (Rx) outstanding at June 28, 2008: 93,311,109 Arthur J. Shannon Vice President of Investor Relations and pharmaceuticals, nutritional products, active pharmaceutical ingredients (API) Global Communications (269) 686-1709 and consumer products. The Company is the world’s largest manufacturer of Annual Meeting Creative services by OTC pharmaceutical products for the store brand market. The annual meeting of shareholders Strategic Communication Advisors will be held at the Allegan County Area and Anderson Design Technical & Education Center, Grand Rapids, Michigan 2891 116th Avenue (M-222), Allegan, Michigan, on November 4, 2008, at 10:00 a.m. (EST) Gary K. Kunkle, Jr. Herman Morris, Jr. Joseph C. Papa Ben-Zion Zilberfarb Retired Chairman and Private practice of law, Chairman, President and Professor of Economics Chief Executive Offi cer, Memphis, Tennessee Chief Executive Offi cer, at Bar-Ilan University DENTSPLY International Inc. Director since 1999 Perrigo Company and consultant Director since 2002 Director since 2006 Director since 2007 Making quality healthcare more affordable. Contents 2 Financial Highlights 3 Letter To Shareholders 14 Market Review 16 Financial Reconciliation Inside Back Cover Shareholder Information 1 Financial Highlights Year Ended Financial Results – June 30, June 28, % Reported (GAAP) 2007 (1) 2008 (1) Change In millions, except shares Net Sales $ 1,447.4 $ 1,822.1 25.9 and per share amounts Operating Income $ 99.7 $ 197.5 98.2 Net Income $ 73.8 $ 135.8 84.0 Diluted Earnings Per Share $ 0.79 $ 1.43 81.0 Average Diluted Shares Outstanding (000’s) 93,807 95,210 1.5 Year Ended Financial Results Adjusted For June 30, June 28, % Non-recurring Items 2007 (1) (2) 2008 (1) (2) Change In millions, except shares Net Sales $ 1,447.4 $ 1,822.1 25.9 and per share amounts Operating Income $ 115.4 $ 218.7 89.5 Net Income $ 83.1 $ 150.1 80.6 Diluted Earnings Per Share $ 0.89 $ 1.58 77.5 Average Diluted Shares Outstanding (000’s) 93,807 95,210 1.5 Net Operating Net Diluted Earnings Sales Income Income Per Share ($ in millions) ($ in millions) ($ in millions) (in dollars) 218.7 1,822.1 1,447.4 150.1 1.58 115.4 83.1 0.89 2007 2008 2007 2008 2007 2008 2007 2008 Perrigo Annual Report 2008 (1) See Item 7 of the Form 10-K report for a discussion of results of operations. (2) See reconciliation of non-GAAP fi nancial measures on page 16. We have excluded certain non-recurring items when monitoring and evaluating Perrigo’s fi nancial results, because we believe this provides important insight into Perrigo’s ongoing operations. 2 Letter To Shareholders Joseph C. Papa Chairman, President and CEO Fiscal 2008 was an exceptional year. We had The Right Place: Perrigo is positioned squarely in record sales, record earnings and record cash the business of providing affordable healthcare. fl ow. These results refl ect the talent, hard work We are the only pharmaceutical company that and commitment of the Perrigo team. has built its business on a combination of OTC, generic Rx and nutritional products – a business Fiscal 2008’s results also reinforce our strategic model that works because it lowers people’s focus on delivering quality, affordable healthcare costs while increasing retailers’ profi ts. healthcare products through a one-of-a-kind pharmaceutical company. The Right Company: Perrigo has a long tradition of delivering shareholder and consumer value by But more than that, these outstanding results creating, producing and marketing a wide range confi rm that it truly is the right time and the right of high-quality pharmaceutical and nutritional place for the right company – Perrigo. products. In doing so, Perrigo has developed The Right Time: Today’s market dynamics – specialized capabilities for high-volume rising healthcare costs, a challenging economy, production, packaging and mass customization. an aging U.S. population, the related growth in This combination of experience and expertise demand for affordable healthcare – all make uniquely positions Perrigo to deliver quality, it the right time for Perrigo’s quality, affordable affordable healthcare products that improve the healthcare products. quality of people’s lives. PERRIGO vs. INDICES FY 2003-2008 Perrigo S & P DJIA NASDAQ NASDAQ HC DRG NBI Price 80% Performance 60% 40% 20% 0% Perrigo Annual Report 2008 -20% -40% JUNE 03 JUNE 04 JUNE 05 JUNE 06 JUNE 07 JUNE 08 3 An Unwavering Commitment to Quality Perrigo’s Strategic Pillars Even after investing more than $15 million in quality-related processes and activities, we were able to reduce our total cost of quality through signifi cant reduction in deviations, Throughout fi scal 2008, we continued our relentless scrap and recalls. focus on the fi ve pillars that we established last year Superior Customer Service as the foundation of our strategic plan: Although our increased sales volume added pressure to customer service demands, our customer service levels for fi scal 2008 improved over fi scal 2007. September 2007 December 2007 January 2008 Final FDA approval for Final FDA approval for Cetirizine Launch of Cetirizine Ciclopirox Topical Hydrochloride 5 and 10 mg Hydrochloride 10 mg Tablets Solution, 8% Tablets (Zyrtec®) (Zyrtec®) ® Perrigo Annual Report 2008 (Penlac Nail Lacquer) Perrigo Annual Report 2008 Acquisition of Galpharm Retail Brand Sales = $92 million Branded Rx Sales = $1.4 billion Healthcare Ltd., Yorkshire, England 4 4 “Perrigo is among the industry leaders in being fi rst-to-market with important new products.” Innovation procurement organization and, where possible, vertical integration between our own API and Being fi rst-to-market with new products in key manufacturing operations. “power categories” is at the forefront of our business strategy. In fi scal 2008, we reinforced People Perrigo’s position as an industry leader by At a time when many companies have reduced introducing important new healthcare products, their workforces, we continued to work hard including Omeprazole, Cetirizine and Clobetasol to recruit, develop and retain people who can Foam, that contributed $220 million to our sales grow along with Perrigo. We are committed to for the year. maintaining environments that foster meaningful Low Cost Structure involvement for all our people. With more than 60 percent of our costs in raw Without question, our commitment to these fi ve materials, we worked continuously to improve pillars contributed signifi cantly to our exceptional the economies of scale and the effi ciency of our performance in fi scal 2008 and is why we’re supply chain through a newly established global optimistic about fi scal 2009. March 2008 Launch of Omeprazole 20 mg February 2008 Retail Brand Sales = $750 million Final FDA approval for OTC Famotidine 10 mg, Calcium Perrigo partner, Teva Pharmaceutical Industries Ltd.
Load more

Recommended publications
  • Bank Hapoalim B.M., Tel-Aviv, Israel
    Bank Hapoalim B.M., Tel-Aviv, Israel 2016 Resolution Plan – Public Section Bank Hapoalim B.M. (“Bank Hapoalim”) is a publicly held banking corporation organized and operating under Israeli law, and subject to comprehensive supervision by the Bank of Israel. In the United States, Bank Hapoalim owns (through PCM-HSU Holdings, Inc., a Delaware-incorporated holding company) Hapoalim Securities USA, a Delaware-incorporated SEC-registered broker-dealer that has offices in New York, California, and Florida. Bank Hapoalim also operates Bank Hapoalim B.M. New York Branch (the “Insured Branch”), a New York state-licensed FDIC-insured branch; Bank Hapoalim B.M. Plaza Branch and Bank Hapoalim Americas Tower Branch, New York state-licensed uninsured branches; Bank Hapoalim B.M. Miami Branch, a Florida state-licensed uninsured branch; and Bank Hapoalim B.M. Los Angeles Representative Office, a California state-licensed representative office. Despite the relatively limited size of its US operations, Bank Hapoalim is subject to US resolution planning requirements under the Dodd-Frank Wall Street Reform and Consumer Protection Act because it has consolidated assets on a global basis of over $50 billion. Because of the relatively limited size and simplified structure of its US operations, Bank Hapoalim’s initial resolution plan, filed in December 2013, was an abbreviated or “tailored” resolution plan and Banks Hapoalim’s second resolution plan, filed in December 2014, was a brief update to its 2013 plan. Based on their review of the 2014 plan, by letter dated July 24, 2015, the FDIC and the Board of Governors of the Federal Reserve System (the “Agencies”) authorized Bank Hapoalim to file a resolution plan that focuses solely on (i) material changes to its 2014 resolution plan; (ii) any actions taken to strengthen the effectiveness of its plan; and (iii) its strategy for ensuring that the Insured Branch will be adequately protected from risks arising from the activities of Bank Hapoalim’s nonbank subsidiaries.
    [Show full text]
  • Fact Sheet:Middle East and Africa ESG Screened Index Equity Sub
    EMEA_INST Managed Pension Funds Limited Middle East and Africa ESG Screened Index Equity Sub-Fund Equities 30 June 2021 Fund Objective Performance ® The Sub-Fund aims to track the FTSE Developed Annualised Fund Benchmark Difference Middle East and Africa ex Controversies ex CW 1 Year (%) 23.30 23.28 0.01 Index, or its recognised replacement or equivalent. 3 Year (%) 4.75 4.84 -0.09 Investment Strategy 5 Year (%) 0.78 0.89 -0.11 The Sub-Fund primarily invests at all times in a Since Inception (%) 4.04 4.18 -0.14 sample of equities constituting the Index with such other securities as MPF shall deem it necessary Cumulative to capture the performance of the Index. Stock 3 Month (%) 11.54 11.51 0.04 index futures can be used for efficient portfolio 1 Year (%) 23.30 23.28 0.01 management. 3 Year (%) 14.95 15.24 -0.29 The following are excluded by the index provider from the index: Controversies (as defined by the ten 5 Year (%) 3.96 4.52 -0.56 principles of the UN Global Compact); Controversial Since Inception (%) 65.75 68.57 -2.81 weapons (including chemical & biological weapons, cluster munitions and anti-personnel landmines). Calendar 2021 (year to date) 9.74 9.71 0.03 Benchmark 2020 -1.28 -1.47 0.19 FTSE Developed Middle East and Africa ex 2019 10.82 11.07 -0.24 Controversies ex CW Index 2018 -0.47 -0.12 -0.35 Structure 2017 -10.77 -10.66 -0.12 Limited Company Past performance is not a guarantee of future results.
    [Show full text]
  • Public Companies Profiting from Illegal Israeli Settlements on Palestinian Land
    Public Companies Profiting from Illegal Israeli Settlements on Palestinian Land Yellow highlighting denotes companies held by the United Methodist General Board of Pension and Health Benefits (GBPHB) as of 12/31/14 I. Public Companies Located in Illegal Settlements ACE AUTO DEPOT LTD. (TLV:ACDP) - owns hardware store in the illegal settlement of Ma'ale Adumim http://www.ace.co.il/default.asp?catid=%7BE79CAE46-40FB-4818-A7BF-FF1C01A96109%7D, http://www.machat.co.il/businesses.php, http://www.nytimes.com/2007/03/14/world/middleeast/14israel.html?_r=3&oref=slogin&oref=slogin&, http://investing.businessweek.com/research/stocks/snapshot/snapshot.asp?ticker=ACDP:IT ALON BLUE SQUARE ISRAEL LTD. (NYSE:BSI) - has facilities in the Barkan and Atarot Industrial Zones and operates supermarkets in many West Bank settlements www.whoprofits.org/company/blue- square-israel, http://www.haaretz.com/business/shefa-shuk-no-more-boycotted-chain-renamed-zol-b-shefa-1.378092, www.bsi.co.il/Common/FilesBinaryWrite.aspx?id=3140 AVGOL INDUSTRIES 1953 LTD. (TLV:AVGL) - has a major manufacturing plant in the Barkan Industrial Zone http://www.unitedmethodistdivestment.com/ReportCorporateResearchTripWestBank2010FinalVersion3.pdf (United Methodist eyewitness report), http://panjiva.com/Avgol-Ltd/1370180, http://www.haaretz.com/print-edition/business/avgol- sees-bright-future-for-nonwoven-textiles-in-china-1.282397 AVIS BUDGET GROUP INC. (NASDAQ:CAR) - leases cars in the illegal settlements of Beitar Illit and Modi’in Illit http://rent.avis.co.il/en/pages/car_rental_israel_stations, http://www.carrentalisrael.com/car-rental- israel.asp?refr= BANK HAPOALIM LTD. (TLV:POLI) - has branches in settlements; provides financing for housing projects in illegal settlements, mortgages for settlers, and financing for the Jerusalem light rail project, which connects illegal settlements with Jerusalem http://www.haaretz.com/print-edition/business/bank-hapoalim-to-lead-financing-for-jerusalem-light-rail-line-1.97706, http://www.whoprofits.org/company/bank-hapoalim BANK LEUMI LE-ISRAEL LTD.
    [Show full text]
  • Domestically Owned Versus Foreign-Owned Banks in Israel
    Domestic bank intermediation: domestically owned versus foreign-owned banks in Israel David Marzuk1 1. The Israeli banking system – an overview A. The structure of the banking system and its scope of activity Israel has a highly developed banking system. At the end of June 2009, there were 23 banking corporations registered in Israel, including 14 commercial banks, two mortgage banks, two joint-service companies and five foreign banks. Despite the spate of financial deregulation in recent years, the Israeli banking sector still plays a key role in the country’s financial system and overall economy. It is also highly concentrated – the five main banking groups (Bank Hapoalim, Bank Leumi, First International Bank, Israel Discount Bank and Mizrahi-Tefahot Bank) together accounted for 94.3% of total assets as of June 2009. The two largest groups (Bank Leumi and Bank Hapoalim) accounted for almost 56.8% of total assets. The sector as a whole and the large banking groups in particular are organised around the concept of “universal” banking, in which commercial banks offer a full range of retail and corporate banking services. Those services include: mortgages, leasing and other forms of finance; brokerage in the local and foreign capital markets; underwriting and investment banking; and numerous specialised services. Furthermore, until the mid-1990s, the banking groups were deeply involved in non-financial activities. However, a law passed in 1996 forced the banks to divest their controlling stakes in non-financial companies and conglomerates (including insurance companies). This development was part of a privatisation process which was almost completed in 2005 (with the important exception of Bank Leumi).
    [Show full text]
  • A Description and Analysis of the Implementation of the Concentration Law and Its Economic
    A Description and Analysis of the Implementation of the Concentration Law and Its Economic Impact on the Israeli Economy Written by: Noam Botosh, Economist | Approved by: Ami Tzadik, Head of the Budgetary Control Department Date: February 25rd 2020 Economic Review www.knesset.gov.il/mmm Knesset Research and Information Center 1 | A Description and Analysis of the Implementation of the Concentration Law and Its Economic Impact on the Israeli Economy Summary This review was written at the request of MK Ofer Shelah, and it addresses the implementation of the Law for Promotion of Competition and Reduction of Concentration, 5774-2013 (herein, "the Concentration Law" or "the Law") and provides a preliminary analysis of the Law's impact on the Israeli economy. A Bank of Israel study from 2009 about business groups showed that, compared to other developed countries, the level of concentration in Israel is high, as reflected in the number of existing business groups, and that these groups possess high levels of financial leverage. The study suggested that this structure of business groups may constitute a risk to Israel's financial stability due to the groups' size and complexity. In October 2010, the Committee on Increasing Competitiveness in the Economy was established in order to examine general market competitiveness in Israel—mainly due to the existence of large business groups— and to recommend possible policy tools to promote market competitiveness. According to the committee's interim report, which was published in October 2011, the ownership structure of public companies in Israel is centralized, and the committee identified a phenomenon of large business groups controlling a large share of real and financial assets.
    [Show full text]
  • Delek Subsidiary, Phoenix, Signs MOU with Bank Hapoalim to Acquire 25% of an Israeli Credit Card Company
    Delek Subsidiary, Phoenix, Signs MOU with Bank Hapoalim to Acquire 25% of an Israeli Credit Card Company Tel Aviv, March 11th 2007, Delek Group (TASE: DLEKG) announced today that its subsidiary company The Phoenix Holdings Ltd. (“the Phoenix”), reported that on March 9th 2007 they signed a Memorandum of Understanding with Bank Hapoalim Ltd. (“Bank Hapoalim”), according to which the Phoenix will acquire 25% of total issued share capital of Isracard Ltd. and Europay (Eurocard) Israel Ltd. (“the Companies”). The Companies are fully controlled by Bank Hapoalim. Please find attached below a translation of the detailed press release as issued today by the Phoenix: Phoenix Holdings Ltd. (“the Company”) announces that on 9th March 2007 they signed a memorandum of understanding with Bank Hapoalim Ltd. (“Bank Hapoalim”), according to which the Phoenix will acquire 25% of total issued share capital of Isracard Ltd. and Europay (Eurocard) Israel Ltd. (“the Companies”), that are currently fully controlled by Bank Hapoalim, and Phoenix will be entitled to representation on the Board of Directors, as agreed in the Memorandum of Understanding. The Company will pay a total consideration based on a combined Companies value of NIS 2.55 billion, subject to adjustments for dividend distributions, if, and so long as, the dividends are distributed prior to the date of the completion and execution of the transaction. Should the Companies complete an Initial Public Offering (“IPO”) within the next 15 months, the combined value of the Companies will be amended to reflect 90% of the Companies' IPO value, if and only in the situation where the valuation of the Companies at IPO is above the combined value of NIS2.7 billion.
    [Show full text]
  • Bank Hapoalim BM, Tel-Aviv, Israel 2013 Resolution Plan
    Bank Hapoalim B.M., Tel-Aviv, Israel 2013 Resolution Plan – Public Section I. Executive summary – 12 C.F.R. §§ 243.8(c), 381.8(c) Bank Hapoalim is a publicly held banking corporation organized and operating under Israeli law, and subject to comprehensive supervision by the Bank of Israel. With total assets of over $100 billion,1 it is one of the largest banking groups in Israel, and conducts a variety of banking, financial and non- banking activities through over 250 offices in Israel and in more than a dozen other countries. In the United States, Bank Hapoalim owns (through PCM-HSU, a Delaware-incorporated holding company) HSUSA, a Delaware-incorporated SEC-registered broker-dealer that has offices in New York, California, and Florida. Bank Hapoalim also operates a New York state-licensed FDIC-insured branch, two New York state-licensed uninsured branches, a Florida state-licensed uninsured branch, and a California state-licensed representative office which began operations on December 16, 2013. These US operations have combined assets of approximately $9 billion. Despite the relatively limited size of its US operations, Bank Hapoalim is subject to US resolution planning requirements under the Dodd-Frank Wall Street Reform and Consumer Protection Act because it has consolidated assets on a global basis of over $50 billion. However, although it is therefore classified as a foreign-based covered company subject to these requirements, Bank Hapoalim is eligible to file an abbreviated or “tailored” resolution plan by virtue of the size and structure of its US operations. In addition to being able to file a tailored plan, Bank Hapoalim also has determined, consistent with the Regulations and applicable guidance, that it has no critical operations, core business lines, or material entities that are located in the United States or conducted in whole or material part in the United States.
    [Show full text]
  • Figure 1.3 A
    Bank Leumi Group Figure 1.3 A. Banking and finance in Israel Bank Leumi Le-Israel Ltd. (1) The structure of Israel's banking system and a Arab Israel Bank Ltd. (1) C. Capital market and financial companies investments in main investee companies , Leumi Mortgage Bank Ltd. (merged with Leumi Card Ltd.(5) Bank Hapoalim Group Bank Leumi Le-Israel Ltd. as of December Leumi Securities and Investments Ltd. (9) December 2012 Leumi Capital Market Services Ltd. (9) 31, 2012) (2) A. Banking and finance in Israel (1) Leumi Leasing and Investments Ltd. (3) The Bank Leumi Le-Israel Trust Co Ltd. (9) Bank Hapoalim Ltd. Leumi Finance Company Ltd. (4) Leumi Partners Ltd. (7)(9) Total assets: NIS 1,301 billion B. Banking and finance abroad (6) Leumi Industrial Development Bank Ltd. (7) D. Non-banking corporations Herfindahl index: H = 0.217 Bank Hapoalim (Switzerland) Ltd. Leumi Real Holdings Ltd. (7) The Israel Corporation Ltd. Bank Hapoalim (Luxembourg) Ltd. Leumi Financial Holdings Ltd. (7) CR 2 = 58% Bank Hapoalim (Cayman Islands) Ltd. B. Banking and finance abroad (6) Bank Hapoalim (Latin America) S.A. Bank Leumi (USA) Bank Pozitif Kredi Ve Kalkinma Bankasi A.S. (with Bank Leumi (UK) plc a holding in JSC Bank Pozitif) Leumi Private Bank S.A. C. Capital market and financial companies (9) Bank Leumi Luxembourg Isracard (5) Bank Leumi Romania Poalim Express Ltd. (5) Leumi International Investments NV Bank Leumi Group, Bank Hapoalim Group, Poalim Capital Markets Ltd. (8) Leumi Re Limited (9) 29% 29% Poalim Sahar Ltd. (9) The Bank Hapoalim Trust Co Ltd.
    [Show full text]
  • The Sale of Israel's Major Credit Card Companies Is Underway
    February. 2017 The sale of Israel’s major credit card companies is underway. Israel’s two largest banks, Bank Leumi and Bank Hapoalim, are now officially compelled to divest their credit card businesses - Leumi Card and Isracard – and the engines are warming up on these sales. Last week, on January 23rd 2017, the Israeli parliament passed the “Strum Law”1, obligating Israel’s two largest banks, Bank Leumi and Bank Hapoalim, to divest their credit card businesses, namely Leumi Card (80% held by Leumi) and Isracard (99.5% held by Hapoalim). These two payment card companies are the largest players in the Israeli payment card market and dominate approx. 76% of the payment card market in Israel (Isracard circa 50% and Leumi Card circa 26%). According to the Strum Law, in order to enhance competition, large Israeli financial and non-financial institutions and corporations are prohibited from purchasing these payment card companies, which in turn promotes and encourages the entrance of foreign players such as PE funds and foreign financial participants (until now prohibited from doing so) to compete for the acquisition of such businesses. Bank Leumi and Bank Hapoalim are each required to divest their credit card companies within three years. An additional year is granted if at the end of three years, the credit card company is taken public with a free float of 25% in public hands, and no more than 40% remains held by the bank. Following the sale, Leumi and Hapoalim will be prohibited from engaging in merchant acquiring (clearing) transactions and from providing credit cards issuance processing (but will be allowed to offer and issue credit cards to their clients, set the rate of card issuance and usage fees and provide credit card holders with credit).
    [Show full text]
  • Israel Charges Toward a More Competitive, Less Monopolistic Economy
    Israel Charges Toward a More Competitive, Less Monopolistic Economy Brian J. Friedman, CFA June 30, 2019 The Israeli economy is in the midst of a profound restructuring, reminiscent of Teddy Roosevelt’s early 20th century trust‐busting in the United States. Beginning in 2013, the Israeli government enacted sweeping reforms that opened the economy for consumers and investors by breaking up monopolies and increasing competition. The divestment of the country’s two biggest credit card businesses in early 2019 is the latest sign of these fundamental economic changes. Until this spring, Israel’s two largest banks – Bank Hapoalim and Bank Leumi – oversaw the country’s most popular credit cards. Bank Hapoalim’s Isracard is the largest credit card brand in Israel, with 5 million cards issued that account for 50% of Israeli credit card transaction volume. Leumi Card and the ICC‐Cal card (controlled by Bank Discount, Israel’s third‐largest bank) evenly split the remaining 50% of the credit card market. According to the Israeli business newspaper, Globes, credit card transactions totaled 300 billion shekels ($84 billion) in 2017 and grew by 7% over the prior year. In 2017, the Israeli government passed “The Law for Increasing Competition and Reducing Concentration in the Israeli Banking Market”. The law ordered Bank Hapoalim and Bank Leumi to divest their credit card businesses. To meet the requirements, Bank Leumi sold Leumi Card to the U.S. private equity firm Warburg Pincus in March 2019. Bank Hapoalim opted instead for an initial public offering (IPO) of its Isracard subsidiary on the Tel‐Aviv Stock Exchange (TASE).
    [Show full text]
  • US Ishares Template
    iShares MSCI Israel ETF EIS Factsheet as of 30-Jun-2021 The iShares MSCI Israel ETF seeks to track the investment results of a broad-based index composed of Israeli equities. KEY FACTS Fund Launch Date 26-Mar-2008 Expense Ratio 0.59% WHY EIS? Benchmark MSCI Israel Capped 1 Exposure to a broad range of companies in Israel Investable Market Index 2 Targeted access to Israeli stocks Number of Holdings 102 Net Assets of Share $156,614,394 3 Use to express a single country view Class Ticker EIS GROWTH OF 10,000 USD SINCE INCEPTION CUSIP 464286632 Exchange NYSE Arca TOP HOLDINGS (%) WIX.COM LTD 8.46 NICE LTD 8.03 CHECK POINT SOFTWARE TECHNOLOGIES 6.83 BANK LEUMI LE ISRAEL 5.79 TEVA PHARMACEUTICAL INDUSTRIES ADR 5.69 BANK HAPOALIM BM 4.78 FIVERR INTERNATIONAL LTD 3.42 ISRAEL DISCOUNT BANK LTD 2.91 KORNIT DIGITAL LTD 2.84 Fund Benchmark CYBER ARK SOFTWARE LTD 2.64 The Growth of $10,000 chart reflects a hypothetical $10,000 investment and assumes reinvestment of 51.39 dividends and capital gains. Fund expenses, including management fees and other expenses were deducted. Holdings are subject to change ANNUALIZED PERFORMANCE 1 Year 3 Years 5 Years 10 Years Since Inception NAV 35.45% 11.29% 9.67% 4.35% 4.56% Market Price 34.94% 11.22% 9.63% 4.28% 4.56% Benchmark 36.03% 11.85% 10.11% 4.68% 5.03% Calendar Year Returns 2020 2019 2018 2017 2016 Fund 11.48 20.91 -4.99 13.08 -4.08 Benchmark 11.94 21.99 -4.70 13.55 -4.06 The performance quoted represents past performance and does not guarantee future results.
    [Show full text]
  • Annual Report 2007
    07ANNUAL REPORT 2007 To Be The Prefered Partner For Tasty And Healthy Success Dear Shareholder, We are pleased to report Frutarom’s results and achievements for 2007, a year in which we continued the implementation of our rapid growth strategy, combining strong organic growth in core activities with acquisitions, while realizing our ambitious goals. In accordance with a strategic plan presented three years ago, we have succeeded in again doubling Frutarom's revenues. Frutarom's sales exceeded the US$ 300 million threshold to total US$ 368 million for 2007. In proforma terms (assuming the acquisitions made during the year had been entirely consolidated with Frutarom's results as of January 1, 2007), our Proforma sales, on an ongoing basis, total US$ 431 million. Frutarom is now firmly established as one of the top ten flavor and fragrance companies in the world. Sales grew by 28.2% to US$ 368 million while Frutarom continued to achieve double digit organic internal growth, substantially higher than the rate experienced by our industry. Gross profit rose by 23.5% to US$ 131 million. Operating profit was US$ 34.5 million and net profit US$ 24.2 million. These excellent results were achieved in a challenging business environment which, as opposed to the past, has been characterized by continued price rises in raw materials used in Frutarom’s production. Price increases have been much greater for many natural ingredients, which make up the majority of ingredients used by Frutarom. To ensure further improvement in future margins, Frutarom continually seeks to raise the selling prices of our products to ensure our future profitability.
    [Show full text]